ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Conditions: ANCA Associated Vasculitis; Cardiovascular Diseases; Kidney Diseases Intervention: Drug: Sparsentan Sponsors: University of Edinburgh; Travere Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials